SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

SynCardia Systems, Inc.

Press Release:

SynCardia Forms European Entity to Address Growing Demand for World's Only Approved Total Artificial Heart

18 New European Hospitals Have Enrolled in SynCardia's Certification Program to Implant the Total Artificial Heart during the Last 15 Months

SynCardia Systems Europe GmbH, led by Managing Directors Oliver Voigt, PhD and Markus Leinberger, RN, will address growing demand for SynCardia’s Total Artificial Heart in Europe. SynCardia Systems Europe GmbH, led by Managing Directors Oliver Voigt, PhD and Markus Leinberger, RN, will address growing demand for SynCardia’s Total Artificial Heart in Europe. TUCSON, Ariz. – Nov. 30, 2011 – SynCardia Systems, Inc., manufacturer of the world's only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today it has formed SynCardia Systems Europe GmbH in Bad Oeynhausen, Germany, to address growing demand for the SynCardia temporary Total Artificial Heart in the European market. SynCardia GmbH will be led by Managing Directors Oliver Voigt, PhD and Markus Leinberger, RN.

"With a dedicated European clinical support team and sales force, SynCardia GmbH will be able to provide hospitals with better customer service and support while continuing to expand current markets and open new ones," said Mr. Leinberger.

SynCardia_Europe_Logo

During the past 15 months, 18 new European hospitals have enrolled in SynCardia's four-phase Certification Program to implant the Total Artificial Heart, bringing the total number of SynCardia customers in Europe to 43 hospitals. There are currently SynCardia Certified Centers in Germany, France, Italy, Austria, Sweden, Great Britain, Turkey, Russia, Lithuania, Slovenia, Australia, Canada and the United States.  

"Many European patients have been supported by the Total Artificial Heart for several years, including our longest supported patient who was transplanted on Sept. 9, 2011, after 1,374 days of support, which is nearly four years," said Dr. Voigt. "As we expand use of the Total Artificial Heart to destination therapy in addition to bridge to transplant, we anticipate that more non-transplant centers in Europe will enroll in the SynCardia Certification Program."

SynCardia GmbH is currently recruiting for a variety of positions including clinical support, sales and administration. Anyone who is interested in applying for an open position should contact Mr. Voigt and Mr. Leinberger via email at Europe@syncardia.com.

Contact SynCardia Systems Europe GmbH
Phone: +49 (0)172 385 26 76 or +49 (0)172 515 17 97
Fax: +49 911 308 44 66266
Email: Europe@syncardia.com
24-Hour Emergency Line: +49 (0)700 SYNCARDIA (796227342)

###

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

Search offcanvas